Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16,802 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial.
Inui N, Suzuki T, Tanaka K, Karayama M, Inoue Y, Mori K, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Matsuura S, Nishimoto K, Matsui T, Asada K, Hashimoto D, Fujii M, Niwa M, Uehara M, Matsuda H, Koda K, Ikeda M, Inami N, Tamiya Y, Kato M, Nakano H, Mino Y, Enomoto N, Suda T. Inui N, et al. Among authors: suzuki y, suzuki t. J Clin Oncol. 2024 Aug 10;42(23):2780-2789. doi: 10.1200/JCO.24.00278. Epub 2024 Jun 4. J Clin Oncol. 2024. PMID: 38833659 Free PMC article. Clinical Trial.
Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting.
Tanaka K, Inui N, Karayama M, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Kusagaya H, Matsuura S, Uto T, Hashimoto D, Matsui T, Asada K, Suda T. Tanaka K, et al. Among authors: suzuki y. Cancer Chemother Pharmacol. 2019 Jul;84(1):147-153. doi: 10.1007/s00280-019-03868-5. Epub 2019 May 13. Cancer Chemother Pharmacol. 2019. PMID: 31087137 Clinical Trial.
Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study.
Nishimoto K, Karayama M, Inui N, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Inami N, Matsuura S, Kaida Y, Matsui T, Asada K, Matsuda H, Fujii M, Toyoshima M, Imokawa S, Suda T. Nishimoto K, et al. Among authors: suzuki y. Med Oncol. 2018 Jun 16;35(7):108. doi: 10.1007/s12032-018-1172-x. Med Oncol. 2018. PMID: 29909581 Clinical Trial.
Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma.
Akiyama N, Karayama M, Inui N, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Inami N, Matsuura S, Kaida Y, Uto T, Matsui T, Asada K, Matsuda H, Fujii M, Toyoshima M, Suda T. Akiyama N, et al. Among authors: suzuki y. Invest New Drugs. 2019 Jun;37(3):531-537. doi: 10.1007/s10637-019-00747-x. Epub 2019 Feb 21. Invest New Drugs. 2019. PMID: 30790149 Clinical Trial.
Efficacy of corticosteroid and intravenous cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis: A propensity score-matched analysis.
Hozumi H, Hasegawa H, Miyashita K, Yasui H, Suzuki Y, Kono M, Karayama M, Furuhashi K, Hashimoto D, Enomoto N, Fujisawa T, Inui N, Nakamura Y, Yokomura K, Nakamura H, Suda T. Hozumi H, et al. Among authors: suzuki y. Respirology. 2019 Aug;24(8):792-798. doi: 10.1111/resp.13506. Epub 2019 Feb 25. Respirology. 2019. PMID: 30803100 Free article.
Once-daily fluticasone furoate/vilanterol combination versus twice-daily budesonide/formoterol combination in the treatment of controlled stable asthma: a randomized crossover trial.
Furuhashi K, Fujisawa T, Hashimoto D, Kamiya Y, Yasui H, Karayama M, Suzuki Y, Hozumi H, Enomoto N, Nakamura Y, Inui N, Suda T. Furuhashi K, et al. Among authors: suzuki y. J Asthma Allergy. 2019 Sep 17;12:253-261. doi: 10.2147/JAA.S223093. eCollection 2019. J Asthma Allergy. 2019. PMID: 31571932 Free PMC article. Review.
Assessment of Immune-Related Interstitial Lung Disease in Patients With NSCLC Treated with Immune Checkpoint Inhibitors: A Multicenter Prospective Study.
Suzuki Y, Karayama M, Uto T, Fujii M, Matsui T, Asada K, Kusagaya H, Kato M, Matsuda H, Matsuura S, Toyoshima M, Mori K, Ito Y, Koyauchi T, Yasui H, Hozumi H, Furuhashi K, Enomoto N, Fujisawa T, Nakamura Y, Inui N, Suda T. Suzuki Y, et al. J Thorac Oncol. 2020 Aug;15(8):1317-1327. doi: 10.1016/j.jtho.2020.04.002. Epub 2020 Apr 11. J Thorac Oncol. 2020. PMID: 32289515 Free article.
Erlotinib and bevacizumab in elderly patients ≥75 years old with non-small cell lung cancer harboring epidermal growth factor receptor mutations.
Aoshima Y, Karayama M, Inui N, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Mikamo M, Matsuura S, Kusagaya H, Kaida Y, Uto T, Hashimoto D, Matsui T, Asada K, Suda T. Aoshima Y, et al. Among authors: suzuki y. Invest New Drugs. 2021 Feb;39(1):210-216. doi: 10.1007/s10637-020-00988-1. Epub 2020 Aug 17. Invest New Drugs. 2021. PMID: 32803701 Clinical Trial.
Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung Cancer.
Inoue Y, Yoshimura K, Nishimoto K, Inui N, Karayama M, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Asada K, Uto T, Fujii M, Matsui T, Matsuura S, Hashimoto D, Toyoshima M, Kusagaya H, Matsuda H, Inami N, Kaida Y, Niwa M, Ito Y, Sugimura H, Suda T. Inoue Y, et al. Among authors: suzuki y. JAMA Netw Open. 2020 Sep 1;3(9):e2011818. doi: 10.1001/jamanetworkopen.2020.11818. JAMA Netw Open. 2020. PMID: 32955570 Free PMC article.
16,802 results
You have reached the last available page of results. Please see the User Guide for more information.